FMP
Armata Pharmaceuticals, Inc.
ARMP
AMEX
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
2.51 USD
-0.155 (-6.18%)
About
ceo
Dr. Deborah L. Birx M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.armatapharma.com
exchange
AMEX
Description
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
CIK
0000921114
ISIN
US04216R1023
CUSIP
04216R102
Address
4503 Glencoe Avenue
Phone
858 829 0829
Country
US
Employee
66
IPO Date
May 20, 1994
Key Executives
